Early antiviral therapy of abidor combined with lopinavir/ritonavir and re-combinant interferonα-2b in patients with novel coronavirus pneumonia in Zhejiang: A multicenter and prospective study

• DOI: 10.3760/cma.j.cn115673-20200224-00069
• Publication Date: 2020-03-02
• Authors: Runan Wei; Nanhong Zheng; Xiangao Jiang; Chunlian Ma; Xiaowei Xu; Shourong Liu; Yongping Chen; Kaijin Xu; Hainv Gao; Jiansheng Zhu; Qingyao Shu; Jifang Sheng; Xiaoqiang Zhang; Minghui Li; Yan Zhang; Mengjie Ma; Xuan Zhang; Shibo Li; Qiujing Wang; Lingjun Ying; Yongjun Zhang; Yunzhen Shi; Lingyan Fan; Wanjun Yu; Huaying Wang; Dandan Sun; Xiaodong Wang; Jichan Shi; Yinghu Chen; Xinsheng Xie; Yunqing Chen; Weihong Wang; Zhaowei Tong; Lingling Tang; Mengfei Zhu; Lingjian Zhang; Lanjuan Li
• Keywords: Lopinavir; Lopinavir/ritonavir; Ritonavir; Combination therapy; Antiviral drug

Objective@#Comparing the benefit of Abidor, lopinavir/ritonavir and recombinant interferon α-2b triple combination antiviral therapy dual to hospitalized novel coronavirus pneumonia 2019 in Zhejiang province.@*Methods@#A multi-center prospective study was carried out compare effect with 15 medical institutions Province. All patients were treated (5 million U, 2 times/d) aerosol inhalation. 196 abidol (200 mg, 3 + lopinavir / ritonavir (2 tablets, 1 time/12 h) as treatment group. 41 The who received divided into three groups: within 48 hours, 3-5 days > 5 after symptom onset. To explore therapeutic effects drugs drugs, well different initiate time. SPSS17.0 software used analyze data.@*Results@#The time virus nucleic acid turning negative (12.2 ± 4.7) drug group, which shorter than that group [(15.0 5.0) days] (t = 6.159, P onset from viral shedding 13 (10,16.8), 17 (13,22) 21 (18-24) respectively (Z 32.983, < 0.01), (11.8±3.9) , (13.5±5.1) (11.2±4.3) d. differences among groups statistically significant (Z=32.983 6.722, P<0.01 or<0.05).@*Conclusions@#The Lopinavir/Litonavir showed hospitalization compared therapy. earlier treatment, shedding.